{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:31:48Z","timestamp":1775079108118,"version":"3.50.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,5]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Nilotinib demonstrated efficacy and a manageable safety profile in pediatric patients with newly diagnosed and pretreated Ph+ CML-CP.<\/jats:p>","DOI":"10.1182\/blood.2019000069","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T21:49:14Z","timestamp":1568238554000},"page":"2036-2045","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome\u2013positive chronic myeloid leukemia"],"prefix":"10.1182","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-054X","authenticated-orcid":false,"given":"Nobuko","family":"Hijiya","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Columbia University Medical Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":false,"given":"Alexey","family":"Maschan","sequence":"additional","affiliation":[{"name":"Dmitrii Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Hematology Oncology Unit, University of Milano Bicocca, Monza e Brianza per il Bambino e la sua Mamma Foundation, Azienda Socio Sanitaria Territoriale Monza, Monza, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5168-3222","authenticated-orcid":false,"given":"Hiroyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Dufour","sequence":"additional","affiliation":[{"name":"IRCCS Hematology Unit, Istituto Giannina Gaslini, Genoa, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Kanagawa Children\u2019s Medical Center, Yokohama, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children\u2019s Hospital, Seoul, South Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Guinipero","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Hematology\/Oncology\/Bone Marrow Transplantation, Nationwide Children\u2019s Hospital, The Ohio State University, Columbus, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Karakas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hematology\/Oncology Unit, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Hospital Ni\u00f1o Jesus, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Ducassou","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire (CHU) Bordeaux, Oncologie H\u00e9matologie P\u00e9diatrique, Universit\u00e9 de Bordeaux, Unit\u00e9 INSERM U1218, Bordeaux, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Hee","family":"Yoo","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology\/Hematology, Erasmus Medical Center-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands;"},{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"Innovative Therapies for Children with Cancer Consortium, Utrecht, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[{"name":"Unit\u00e9 d\u2019Onco-H\u00e9matologie P\u00e9diatrique, Clinical Investigation Center 1402 INSERM, CHU de Poitiers, Poitiers, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Aimone","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Allepuz","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Quenet","sequence":"additional","affiliation":[{"name":"Clinical Development and Analytics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Hourcade-Potelleret","sequence":"additional","affiliation":[{"name":"Pharmacokinetics Sciences, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Hertle","sequence":"additional","affiliation":[{"name":"Trial Management, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darintr","family":"Sosothikul","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hematology and Oncology Division, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019120506584516300_B1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"2019120506584516300_B2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","article-title":"Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation","volume":"2010","author":"Suttorp","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019120506584516300_B3","article-title":"Cancer incidence and survival among children and adolescents","author":"Ries"},{"key":"2019120506584516300_B4","unstructured":"Novartis Pharmaceuticals Corporation\n          . Novartis drug Tasigna (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children. https:\/\/www.novartis.com\/news\/media-releases\/novartis-drug-tasignar-nilotinib-secures-eu-approval-first-and-second-line-treatment-ph-cml-cp-children. Accessed 20 June 2019."},{"key":"2019120506584516300_B5","unstructured":"U.S. Food and Drug Administration\n          . FDA approves dasatinib for pediatric patients with CML. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-dasatinib-pediatric-patients-cml. Accessed 20 June 2019."},{"issue":"7","key":"2019120506584516300_B6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"issue":"20","key":"2019120506584516300_B7","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","article-title":"Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial","volume":"29","author":"Millot","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019120506584516300_B8","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2019120506584516300_B9","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019120506584516300_B10","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2019120506584516300_B11","article-title":"Nilotinib in pediatric patients with Philadelphia chromosome\u2013positive (Ph+) chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (AML): a pharmacokinetic study [abstract]","volume":"64","author":"Hijiya","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2019120506584516300_B12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019120506584516300_B13","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"issue":"35","key":"2019120506584516300_B14","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor\u2013associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019120506584516300_B15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"2019120506584516300_B16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019120506584516300_B17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019120506584516300_B18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"issue":"12","key":"2019120506584516300_B19","doi-asserted-by":"crossref","first-page":"CR721","DOI":"10.12659\/MSM.883599","article-title":"Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment","volume":"18","author":"Jaeger","year":"2012","journal-title":"Med Sci Monit"},{"issue":"3","key":"2019120506584516300_B20","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"issue":"18","key":"2019120506584516300_B21","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"issue":"5","key":"2019120506584516300_B22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","article-title":"Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase","volume":"68","author":"Larson","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2019120506584516300_B23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pbc.23031","article-title":"Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children\u2019s Oncology Group","volume":"57","author":"Champagne","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2019120506584516300_B24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience","volume":"170","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2019120506584516300_B25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2019120506584516300_B26","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019120506584516300_B27","first-page":"421","article-title":"The \u201chit hard and hit early\u201d approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network clinical practice guidelines for routine practice","volume":"11","author":"Akard","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"2019120506584516300_B28","unstructured":"Novartis Pharmaceuticals\n          . Tasigna (nilotinib): highlights of prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2018. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/tasigna.pdf"},{"key":"2019120506584516300_B29","unstructured":"Bristol-Myers Squibb\n          . Sprycel (dasatinib) highlights of prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2017. https:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf."},{"issue":"7","key":"2019120506584516300_B30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.2010.30.7231","article-title":"Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Children\u2019s Oncology Group Phase I Consortium","volume":"29","author":"Aplenc","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019120506584516300_B31","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019120506584516300_B32","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019120506584516300_B33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"22","key":"2019120506584516300_B34","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2019120506584516300_B35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"2019120506584516300_B36","unstructured":"Pharmaceuticals and Medical Devices Agency\n          . Tasigna prescribing information [Japanese]. http:\/\/www info pmda go jp\/go\/pack\/4291021M1020_1_26\/. Accessed 21 February 2018."},{"key":"2019120506584516300_bib37","year":"2018"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/23\/2036\/1545301\/bloodbld2019000069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/23\/2036\/1545301\/bloodbld2019000069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T06:58:59Z","timestamp":1575529139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/23\/2036\/374975\/Phase-2-study-of-nilotinib-in-pediatric-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":37,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000069","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]}}}